Bank of Montreal Can Sells 2,059,760 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Bank of Montreal Can decreased its position in ADMA Biologics, Inc. (NASDAQ:ADMA - Free Report) by 98.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 26,562 shares of the biotechnology company's stock after selling 2,059,760 shares during the quarter. Bank of Montreal Can's holdings in ADMA Biologics were worth $456,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. GAMMA Investing LLC increased its position in ADMA Biologics by 106.6% in the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 967 shares during the last quarter. Mark Sheptoff Financial Planning LLC bought a new stake in shares of ADMA Biologics in the 4th quarter worth about $35,000. Vision Financial Markets LLC purchased a new stake in shares of ADMA Biologics during the 4th quarter valued at about $51,000. AlphaQuest LLC bought a new position in shares of ADMA Biologics in the 4th quarter valued at about $84,000. Finally, CIBC Private Wealth Group LLC grew its position in ADMA Biologics by 137.1% in the fourth quarter. CIBC Private Wealth Group LLC now owns 5,108 shares of the biotechnology company's stock worth $95,000 after acquiring an additional 2,954 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

ADMA Biologics Trading Down 2.1 %

Shares of ADMA stock traded down $0.47 during trading hours on Friday, reaching $21.86. 2,611,436 shares of the stock were exchanged, compared to its average volume of 3,636,536. The firm has a market capitalization of $5.17 billion, a price-to-earnings ratio of 78.07 and a beta of 0.53. ADMA Biologics, Inc. has a 12-month low of $6.40 and a 12-month high of $23.64. The company's 50-day moving average price is $18.80 and its 200-day moving average price is $18.28. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of ADMA Biologics in a research note on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.